Watch LSTA. Know when insiders buy.
One email the day a filing lands. Free.
LSTA
LISATA THERAPEUTICS, INC.
1.70
−0.04 −2.30%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $15.3MP/E —DIV YIELD —FCF YIELD -80.44%REV TTM $100K −90.7%NET INCOME −$14.6MNET CASH $5.5M52W 0.99 – 5.04SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$4M | −$2.9M | — | -0.32 | −$2.6M | $0 | −$2.6M | Aug 6 |
| Q1 2026 · Mar 31 | $0 | — | — | −$4.9M | −$4.5M | — | -0.50 | −$3.1M | $0 | −$3.1M | May 11 |
| Q4 2025 · Dec 31derived | $100K | −90.0% | — | −$3.1M | −$3M | — | -0.33 | −$3.2M | $0 | −$3.2M | Mar 12 |
| Q3 2025 · Sep 30 | $0 | — | — | −$4.4M | −$4.2M | — | -0.49 | −$3.3M | $0 | −$3.3M | Nov 6 |
| Q2 2025 · Jun 30 | $70K | — | — | −$4.9M | −$4.7M | — | -0.54 | −$4M | $0 | −$4M | Aug 6 |
| Q1 2025 · Mar 31 | $0 | — | — | −$5.8M | −$4.7M | — | -0.55 | −$5.4M | $28K | −$5.4M | May 11 |
| Q4 2024 · Dec 31derived | $1M | — | — | −$4.9M | −$4.6M | — | -0.55 | −$4.5M | $0 | −$4.5M | Mar 12 |
| Q3 2024 · Sep 30 | $0 | — | — | −$5.3M | −$4.9M | — | -0.59 | −$2.5M | $0 | −$2.5M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$5.5M | −$5M | — | -0.61 | −$5.3M | $0 | −$5.3M | Aug 7 |
| Q1 2024 · Mar 31 | $0 | — | — | −$6.6M | −$5.4M | — | -0.65 | −$7M | $0 | −$7M | May 8 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$6M | −$5.4M | — | -0.66 | −$4.1M | $0 | −$4.1M | Feb 27 |
| Q3 2023 · Sep 30 | $0 | — | — | −$6M | −$5.3M | — | -0.65 | −$3.6M | $0 | −$3.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $170K | — | −$18.2M | −$16.6M | -9756.5% | -1.91 | −$15.9M | $28K | −$16M | — | — |
| FY2024 · to Dec 31 | $1M | — | −$22.4M | −$20M | -1998.5% | -2.40 | −$19.4M | $0 | −$19.4M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$25.7M | −$20.8M | — | -2.58 | −$20M | $0 | −$20M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$57.6M | −$54.2M | — | -10.47 | −$21.2M | $285K | −$21.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$29.1M | −$27.5M | — | -7.45 | −$22.2M | $60K | −$22.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$19.1M | −$8.2M | — | -0.53 | −$8.8M | $20K | −$8.8M | — | — |
Every number comes from LISATA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.